

(Signature)
Sub C1
Docket No. 252312005704

--22. (New) A composition comprising a plurality of a conjugate, wherein said conjugate comprises:

a chemically defined valency platform molecule comprising branching groups, wherein the valency platform molecule contains a specific number of attachment sites whereby the valency of said platform molecule is defined; and

a multiplicity of biologically active molecules conjugated to the chemically defined valency platform molecule at said attachment sites;

wherein the molecular weight of the valency platform molecules is substantially homogeneous; and

wherein the valency platform molecules have attachment sites at the same location.

23. (New) The composition of claim 22, wherein the branching groups are derived from a functional group selected from the group consisting of diamino acid, triamine, and amino diacid.

24. (New) The composition of claim 22, wherein the multiplicity of biologically active molecules are the same.

25. (New) The composition of claim 22 comprising conjugates, wherein a said conjugate comprises four biologically active molecules.

26. (New) The composition of claim 22, wherein the biologically active molecule comprises a polynucleotide.

27. (New) The composition of claim 26, wherein the polynucleotide is a polynucleotide duplex.

28. (New) The composition of claim 26, wherein the polynucleotide is a polynucleotide duplex of 20 to 50 bp in length.

Q5
Cont

29. (New) The composition of claim 26, wherein the polynucleotide is synthetic.

30. (New) The composition of claim 26, wherein the polynucleotide is prepared by molecular cloning.

31. (New) The composition of claim 26, wherein the polynucleotide is a polynucleotide duplex having a B DNA type helical structure.

32. (New) The composition of claim 22, wherein the biologically active molecule is selected from the group consisting of carbohydrates, lipids, lipopolysaccharides, peptides, proteins, glycoproteins, and drugs.

33. (New) The composition of claim 22, wherein the biologically active molecule is selected from the group consisting of analogs of immunogens, haptens, mimotopes, and aptamers.

34. (New) The composition of claim 22, wherein the chemically defined valency platform molecule is substantially nonimmunogenic.

35. (New) The composition of claim 22, wherein the composition comprises a pharmaceutically acceptable carrier.

Ins A1

36. (New) The composition of claim 35, wherein the composition is suitable for treating antibody mediated pathologies.

37. (New) The composition of claim 35, wherein the composition is suitable for injection.

38. (New) The composition of claim 35, wherein the composition is suitable for the treatment of human systemic lupus erythematosus.

OS
cont

39. (New) The composition of claim 22, wherein the conjugate comprises polyethylene glycol.

40. (New) The composition of claim 22, wherein the valency platform molecule comprises polyethylene glycol.

41. (New) The composition of claim 22, wherein the conjugate comprises polyethylene glycol having the formula $-\text{CH}_2(\text{CH}_2\text{OCH}_2)_r\text{CH}_2-$, wherein $r=0$ to 300.

42. (New) The composition of claim 22, wherein the valency platform molecule comprises polyethylene glycol having the formula $-\text{CH}_2(\text{CH}_2\text{OCH}_2)_r\text{CH}_2-$, wherein $r=0$ to 300.

43. (New) The composition of claim 22, wherein the valency platform molecule comprises triethylene glycol.

44. (New) A method of making the composition of claim 22, the method comprising forming said conjugates by covalently bonding the biologically active molecules to the chemically-defined valency platform molecule to form a conjugate.

45. (New) A method of making the composition of claim 22, wherein the biologically active molecule is a polynucleotide duplex, the method comprising forming said conjugates by: reacting a multiplicity of single-stranded polynucleotides, each of which is at least about 20 nucleotides in length and has a functional group at or proximate one of its termini, with functional groups on the chemically-defined valency platform molecule to form the conjugate; and

*Q5
cont*
annealing complementary single-stranded polynucleotides to the single-stranded polynucleotides conjugated to the chemically-defined valency platform molecule to form pendant chains of double-stranded DNA. --

Add
C1

00252312005704